Castle Biosciences (CSTL) Non-Current Deffered Revenue (2018 - 2021)

Castle Biosciences has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $986000.0 for Q3 2021.

• Non-Current Deffered Revenue for Q3 2021 came in at $986000.0, down 13.51% year-over-year; the trailing twelve-month figure through Sep 2021 was $986000.0 (down 13.51% YoY), and the FY2020 annual result was $1.7 million, changed N/A from the prior year.
• Non-Current Deffered Revenue came in at $986000.0 for Q3 2021 at Castle Biosciences, down from $995000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $1.7 million in Q4 2020 to a low of $44000.0 in Q4 2018.
• The 4-year median for Non-Current Deffered Revenue is $941000.0 (2020), against an average of $667521.8.
• Across the five-year window, Non-Current Deffered Revenue soared 1935.5% in 2020 and slipped 13.51% in 2021, its largest moves.
• Castle Biosciences' Non-Current Deffered Revenue stood at $44000.0 in 2018, then advanced by 27.29% to $56006.0 in 2019, then surged by 2997.88% to $1.7 million in 2020, then slumped by 43.17% to $986000.0 in 2021.
• The last three Non-Current Deffered Revenue figures came in at $986000.0 (Q3 2021), $995000.0 (Q1 2021), and $1.7 million (Q4 2020), per Business Quant data.